Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics Inc (TRDA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
7.86 -0.01 (-0.13%) 04/16/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 7.86 unch (unch) 16:01 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
7.56
Day High
7.89
Open 7.84
Previous Close 7.87 7.87
Volume 179,700 179,700
Avg Vol 164,095 164,095
Stochastic %K 26.22% 26.22%
Weighted Alpha -52.69 -52.69
5-Day Change -0.41 (-4.96%) -0.41 (-4.96%)
52-Week Range 7.10 - 21.79 7.10 - 21.79
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 295,873
  • Shares Outstanding, K 37,595
  • Annual Sales, $ 210,780 K
  • Annual Income, $ 65,630 K
  • EBIT $ 47 M
  • EBITDA $ 41 M
  • 60-Month Beta 0.04
  • Price/Sales 1.41
  • Price/Cash Flow 4.99
  • Price/Book 0.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.78
  • Number of Estimates 4
  • High Estimate -0.70
  • Low Estimate -0.92
  • Prior Year 0.68
  • Growth Rate Est. (year over year) -214.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.10 +10.70%
on 04/09/25
Period Open: 10.81
11.36 -30.81%
on 03/17/25
-2.95 (-27.29%)
since 03/14/25
3-Month
7.10 +10.70%
on 04/09/25
Period Open: 12.54
14.27 -44.92%
on 02/05/25
-4.68 (-37.32%)
since 01/16/25
52-Week
7.10 +10.70%
on 04/09/25
Period Open: 12.72
21.79 -63.93%
on 12/09/24
-4.86 (-38.21%)
since 04/16/24

Most Recent Stories

More News
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

TRDA : 7.86 (-0.13%)
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

TRDA : 7.86 (-0.13%)
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

TRDA : 7.86 (-0.13%)
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

TRDA : 7.86 (-0.13%)
Best Momentum Stocks to Buy for December 30th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:CoreCard Corporation CCRD: This technology solutions and processing services company...

NRXP : 1.9300 (-2.03%)
TRDA : 7.86 (-0.13%)
CCRD : 18.52 (+0.16%)
New Strong Buy Stocks for December 30th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:CoreCard Corporation CCRD: This technology solutions and processing services company has seen the Zacks Consensus Estimate for its...

APPN : 26.92 (-1.86%)
USNA : 23.43 (-2.42%)
NRXP : 1.9300 (-2.03%)
TRDA : 7.86 (-0.13%)
CCRD : 18.52 (+0.16%)
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TRDA : 7.86 (-0.13%)
Insider Sale: Chief Financial Officer of $TRDA (TRDA) Sells 1,000 Shares

KORY JAMES WENTWORTH, the Chief Financial Officer of $TRDA ($TRDA), sold 1,000 shares of the company on 11-29-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

TRDA : 7.86 (-0.13%)
Entrada Therapeutics Reports Third Quarter 2024 Financial Results

TRDA : 7.86 (-0.13%)
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

TRDA : 7.86 (-0.13%)

Business Summary

Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 8.31
2nd Resistance Point 8.10
1st Resistance Point 7.98
Last Price 7.86
1st Support Level 7.65
2nd Support Level 7.44
3rd Support Level 7.32

See More

52-Week High 21.79
Fibonacci 61.8% 16.18
Fibonacci 50% 14.45
Fibonacci 38.2% 12.71
Last Price 7.86
52-Week Low 7.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro